A multiple-center, non-randomized, open-label study to investigate the effect of various degrees of renal impairment on the pharmacokinetics of a single intravenous dose of RO7223280

Start Date04 May 2023

Sponsor / Collaborator-

ISRCTN60758609

/ RecruitingPhase 1

A sponsor-open, randomized, placebo-controlled, phase I study to investigate the pharmacokinetics, safety, and tolerability of RO7223280 in healthy Chinese participants following single IV dose administration

Start Date24 Feb 2023

Sponsor / Collaborator-

100 Clinical Results associated with Zosurabalpin

100 Translational Medicine associated with Zosurabalpin

100 Patents (Medical) associated with Zosurabalpin

Literatures (Medical) associated with Zosurabalpin

01 Jan 2025·Science Bulletin

Zosurabalpin like petrichor: a novel antibiotic class with unprecedented target towards Acinetobacter baumannii

Article

Author: Wu, Min ; Wen, Yajin ; Huang, Yongye ; Xia, Zhenwei ; Zhi, Yinghao

A review.A recent study published in Nature found that zosurabalpin, an optimized tethered macrocyclic peptide (MCP) antibiotic, can kill Acinetobacter baumannii by inhibiting the transport of lipopolysaccharide (LPS) from the bacterial plasma membrane to its outer membrane.This breakthrough in the search for new antibiotics, like petrichor, breathes new life into the prospect of treating drug-resistant bacteria like carbapenem-resistant Acinetobacter baumannii (CRAB).Antibiotic resistance has become a crisis threatening public health and modern medicine, and A. baumannii is a frequent pathogen with extensive antibiotic resistance.The authors identified tethered MCPs, a novel class of smallmol. antibiotics specific for A. baumannii, and found clin. candidate zosurabalpin to have similar antibacterial activity for both antibiotic-susceptible and multidrug-resistant A. baumannii strains.The drug mechanism involves blocking the entrance of LPS from the cytoplasmic membrane to the outer membrane, leading to LPS dynamic accumulation in the cytoplasm and ultimately cell death.Zosurabalpin, a new antibiotic, has been confirmed to be effective against severe invasive A. baumannii infection in clin. patients.Its min. inhibitory concentration (MIC) is 1 mg, compared to other antibiotics like tigecycline, colistin, and meropenem.Zosurabalpin has favorable non-clin. pharmacokinetic and safety profiles and therapeutic efficacy in vivo.Zosurabalpin is currently undergoing a phase I clin. trial to evaluate its safety and effect in patients with CRAB infection.The study used machine learning methods and artificial intelligence and deep learning models to identify similarities in compound-induced phenotypes, indicating a similar mode of action.

01 Dec 2024·Expert Review of Anti-infective Therapy

Potentially effective antimicrobial treatment for pneumonia caused by isolates of carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii complex species: what can we expect in the future?

Review

Author: Jean, Shio-Shin ; Hsueh, Po-Ren ; Liu, Chia-Ying ; Liu, I-Min ; Lai, Chih-Cheng ; Huang, Tzu-Yu ; Hsieh, Po-Chuen

INTRODUCTIONAcinetobacter baumannii complex (Abc) is currently a significant cause of difficult-to-treat pneumonia. Due to the high prevalence rates of carbapenem- and extensively drug-resistant (CR, XDR) phenotypes, limited antibiotic options are available for the effective treatment of pneumonia caused by CR/XDR-Abc.AREAS COVEREDIn vitro susceptibility data, relevant pharmacokinetic profiles (especially the penetration ratios from plasma into epithelial-lining fluid), and pharmacodynamic indices of key antibiotics against CR/XDR-Abc are reviewed.EXPERT OPINIONDoubling the routine intravenous maintenance dosages of conventional tigecycline (100 mg every 12 h) and minocycline (200 mg every 12 h) might be recommended for the effective treatment of pneumonia caused by CR/XDR-Abc. Nebulized polymyxin E, novel parenteral rifabutin BV100, and new polymyxin derivatives (SPR206, MRX-8, and QPX9003) could be considered supplementary combination options with other antibiotic classes. Regarding other novel antibiotics, the potency of sulbactam-durlobactam (1 g/1 g infused over 3 h every 6 h intravenously) combined with imipenem-cilastatin, and the β-lactamase inhibitor xeruborbactam, is promising. Continuous infusion of full-dose cefiderocol is likely an effective treatment regimen for CR/XDR-Abc pneumonia. Zosurabalpin exhibits potent anti-CR/XDR-Abc activity in vitro, but its practical use in clinical therapy remains to be evaluated. The clinical application of antimicrobial peptides and bacteriophages requires validation.

01 Aug 2024·MedComm

Zosurabalpin: a novel tethered macrocyclic peptide antibiotic that kills carbapenem‐resistant Acinetobacter baumannii

Article

Author: Zhang, Feng ; Zheng, Quan ; Weng, Qi

This paper is about Zosurabalpin novel tethered macrocyclic peptide antibiotic that kills carbapenem-resistant Acinetobacter baumannii.In two recent studies published back-to-back in Nature, Bradley′s and Kahne′s teams reported a novel tethered macrocyclic peptide (MCP) antibiotic called zosurabalpin, which targets the LptB2FGC complex in the inner membrane to block lipopolysaccharide (LPS) transport, leading to the accumulation of this endotoxin in the cell, ultimately resulting in the death of the bacteria .Zosurabalpin not only showed excellent antibacterial activity against carbapenem-resistant Acinetobacter baumannii (CRAB) in vivo and in vitro, but is also expected to break through the resistance mechanisms of existing antibiotics, offering new prospects for clin. treatment.A.baumannii, a Gram-neg. bacterium with an outer membrane containing LPS, is resistant to penetration by a wide range of antibiotics, making it difficult to kill. It.It Is one of the common causative agents of hospital-acquired infections and results in hospital-acquired pneumonia, bloodstream infections, urinary tract infections, and soft tissue skin infections.In summary, zosurabalpin, with its distinctive mechanism of action, selective antibacterial activity, highly potent in vitro and in vivo efficacy, and favorable tolerability, exhibits notable competitive advantages in the domain of CRAB therapy.First, zosurabalpin is highly selective for CRAB and has limited activity against other Gram-neg. and Gram-pos. bacteria, helping to minimize the impact on normal flora and thus potentially reducing associated side effects.Second, due to the novel mechanism of action of zosurabalpin, CRAB currently lacks an effective defense mechanism in the face of zosurabalpin, which will provide a new option for the clin. treatment of drug-resistant strains.Consequently, it is imperative to investigate the potential of combining zosurabalpin with other antibiotics to enhance thera- peutic efficacy and impede the emergence of resistance.We can also further chem. modify MCPs to improve their stability, bioavailability, and reduce potential side effects.

News (Medical) associated with Zosurabalpin

09 Apr 2024

·www.pharmaceutical-technology.com

Basilea wins CARB-X grant for new antibody development

Basilea may receive additional funding from CARB-X for further preclinical and early clinical development, contingent on certain undisclosed project milestones, as per the company. Image Credit: Marian Weyo / Shutterstock. Switzerland-based Basilea Pharmaceutica has received a $0.9m grant from the global non-profit, Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), to develop a new antibiotic. Free Whitepaper PepSetsTM and their Applications Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides. Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with Mimotopes Thematic and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. You will receive an email shortly. Please check for download the Whitepaper. Go deeper with GlobalData Reports LOA and PTSR Model - Bemcentinib in Refractory Acute Myeloid Leukemia Reports LOA and PTSR Model - Briquilimab in Beta Thalassaemia Premium Insights The gold standard of business intelligence. Find out more The grant will fund the preclinical development of an antibiotic candidate until the candidate’s nomination, which is expected in H2 this year. Basilea added that the company may receive additional funding from CARB-X for further preclinical and early clinical development, contingent on certain undisclosed project milestones. The antibiotic programme that received funding was developed using the Spexis’ outer membrane protein targeting antibiotics (OMPTA) technology, which Basilea acquired in January . The OMPTA class of antibiotics binds dually to lipopolysaccharide and outer-membrane proteins. These proteins provide structural integrity and a permeability barrier to protect the gram-negative bacterial cell. Therefore, any disruption in the function of these proteins can cause the bacteria to die. See Also: Prothea debuts with $13m to develop cancer diagnostics and treatment Medicxi and Starpharma to develop dendrimer-based cancer treatments The CARB-X’s funding is provided through the US Biomedical Advanced Research and Development Authority (BARDA) ’s antibacterial branch. Basilea has previously received funds from the US Government to develop its portfolio of antibacterials and antifungals. The company’s recently approved antibiotic Zevtera (ceftobiprole) was developed through subsidised funding from BARDA . Antimicrobial resistance (AMR) has become a growing issue in recent years, with the World Health Organisation (WHO) declaring it one of the top global public health and development threats. The US bacterial infection market is expected to be worth $4.1bn by 2024, according to GlobalData . GlobalData is the parent company of Pharmaceutical Technology . In light of the growing demand, there has been an increased interest in developing new therapies to combat this issue. In September 2023, Novo Holdings acquired Boston-based Paratek Pharmaceuticals to bolster its AMR expertise. Paratek’s portfolio consisted of Nuzyra (omadacycline), a marketed once-a-day oral and intravenous antibiotic indicated for acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). Another antibiotic currently in development is Roche’s zosurabalpin. It is classified under a new antibiotic class of drugs called tethered macrocyclic peptides. Zosurabalpin targets the lipopolysaccharide (LPS) transport systems, which is important for maintaining bacterial cell structure among other functions. Early R&D project coverage on Pharmaceutical Technology is supported by Mimotopes. Editorial content is independently produced and follows highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content. Free Whitepaper PepSetsTM and their Applications Peptide libraries are a powerful tool in biological research for screening large numbers of peptides in the search for the few, critical bioactive peptides. Mimotopes PepSets are custom-synthesized peptide libraries supplied unpuried for fast, efcient screening work. These sets of chemically synthesized individual peptides are made on a small scale using Mimotopes’ unique proprietary parallel array synthesis platform. PepSets comprising hundreds, or even thousands of peptides, are rapidly synthesized and shipped within a few weeks of ordering. By Mimotopes Thematic Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Herzegovina (+387) Botswana (+267) Brazil (+55) Brunei (+673) Bulgaria (+359) Burkina Faso (+226) Burundi (+257) Cambodia (+855) Cameroon (+237) Canada (+1) Cape Verde Islands (+238) Cayman Islands (+1345) Central African Republic (+236) Chile (+56) China (+86) Colombia (+57) Comoros (+269) Congo (+242) Cook Islands (+682) Costa Rica (+506) Croatia (+385) Cuba (+53) Cyprus North (+90392) Cyprus South (+357) Czech Republic (+42) Denmark (+45) Djibouti (+253) Dominica (+1809) Dominican Republic (+1809) Ecuador (+593) Egypt (+20) El Salvador (+503) Equatorial Guinea (+240) Eritrea (+291) Estonia (+372) Ethiopia (+251) Falkland Islands (+500) Faroe Islands (+298) Fiji (+679) Finland (+358) France (+33) French Guiana (+594) French Polynesia (+689) Gabon (+241) Gambia (+220) Georgia (+7880) Germany (+49) Ghana (+233) Gibraltar (+350) Greece (+30) Greenland (+299) Grenada (+1473) Guadeloupe (+590) Guam (+671) Guatemala (+502) Guinea (+224) Guinea - Bissau (+245) Guyana (+592) Haiti (+509) Honduras (+504) Hong Kong (+852) Hungary (+36) Iceland (+354) India (+91) Indonesia (+62) Iran (+98) Iraq (+964) Ireland (+353) Israel (+972) Italy (+39) Jamaica (+1876) Japan (+81) Jordan (+962) Kazakhstan (+7) Kenya (+254) Kiribati (+686) Korea North (+850) Korea South (+82) Kuwait (+965) Kyrgyzstan (+996) Laos (+856) Latvia (+371) Lebanon (+961) Lesotho (+266) Liberia (+231) Libya (+218) Liechtenstein (+417) Lithuania (+370) Luxembourg (+352) Macao (+853) Macedonia (+389) Madagascar (+261) Malawi (+265) Malaysia (+60) Maldives (+960) Mali (+223) Malta (+356) Marshall Islands (+692) Martinique (+596) Mauritania (+222) Mayotte (+269) Mexico (+52) Micronesia (+691) Moldova (+373) Monaco (+377) Mongolia (+976) Montserrat (+1664) Morocco (+212) Mozambique (+258) Myanmar (+95) Namibia (+264) Nauru (+674) Nepal (+977) Netherlands (+31) New Caledonia (+687) New Zealand (+64) Nicaragua (+505) Niger (+227) Nigeria (+234) Niue (+683) Norfolk Islands (+672) Northern Marianas (+670) Norway (+47) Oman (+968) Palau (+680) Panama (+507) Papua New Guinea (+675) Paraguay (+595) Peru (+51) Philippines (+63) Poland (+48) Portugal (+351) Puerto Rico (+1787) Qatar (+974) Reunion (+262) Romania (+40) Russia (+7) Rwanda (+250) San Marino (+378) Sao Tome & Principe (+239) Saudi Arabia (+966) Senegal (+221) Serbia (+381) Seychelles (+248) Sierra Leone (+232) Singapore (+65) Slovak Republic (+421) Slovenia (+386) Solomon Islands (+677) Somalia (+252) South Africa (+27) Spain (+34) Sri Lanka (+94) St. Helena (+290) St. Kitts (+1869) St. Lucia (+1758) Sudan (+249) Suriname (+597) Swaziland (+268) Sweden (+46) Switzerland (+41) Syria (+963) Taiwan (+886) Tajikstan (+7) Thailand (+66) Togo (+228) Tonga (+676) Trinidad & Tobago (+1868) Tunisia (+216) Turkey (+90) Turkmenistan (+7) Turkmenistan (+993) Turks & Caicos Islands (+1649) Tuvalu (+688) Uganda (+256) Ukraine (+380) United Arab Emirates (+971) Uruguay (+598) Uzbekistan (+7) Vanuatu (+678) Vatican City (+379) Venezuela (+58) Vietnam (+84) Virgin Islands - British (+1284) Virgin Islands - US (+1340) Wallis & Futuna (+681) Yemen (North)(+969) Yemen (South)(+967) Zambia (+260) Zimbabwe (+263) Country * UK USA Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos Islands Colombia Comoros Congo Democratic Republic of the Congo Cook Islands Costa Rica Côte d"Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati North Korea South Korea Kuwait Kyrgyzstan Lao Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates US Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam British Virgin Islands US Virgin Islands Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Kosovo By downloading this case study, you acknowledge that GlobalData may share your information with Mimotopes Thematic and that your personal data will be used as described in their Privacy Policy Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address. Thank you. You will receive an email shortly. Please check for download the Whitepaper.

AcquisitionDrug Approval

21 Mar 2024

·www.pharmaceutical-technology.com

Early AMR pipeline looks beyond traditional antibiotics

Antimicrobial resistance (AMR) has been identified as a major global threat by the WHO. Image Credit: Inkoly / Shutterstock. Despite being tagged as a global threat, the pipeline for new therapies against antimicrobial resistance (AMR) is fairly weak, with most candidates in preclinical and early clinical development. AMR has been identified as a major global threat by the World Health Organization (WHO). One of the reasons for the resistance is the overuse and misuse of antibiotics . Many reasons have been cited for an underdeveloped AMR pipeline, chief among them is a lack of commercial incentives . The research into the development of new therapies against AMR was a key focus area at the 2024 ELRIG UK’s Research and Innovation – Drug Discovery (RI2024) conference that took place in Manchester from 20-21 March. One of the most clinically advanced candidates in the lineup that was discussed at the meeting was Roche’s zosurabalpin . It is classified under a new antibiotic class of drugs called tethered macrocyclic peptides. Zosurabalpin targets the lipopolysaccharide (LPS) transport systems, which is important for maintaining bacterial cell structure among other functions. The drug is being developed for the treatment of carbapenem-resistant acinetobacter baumanni (CRAB), which has been categorised as a ‘priority 1 pathogen’ by the WHO indicating an urgent need for therapies against these pathogens. Zosurabalpin was evaluated in Phase I trials in both healthy volunteers (NCT04605718) and critically ill patients with bacterial infections (NCT05614895) to determine the pharmacokinetics, safety, and tolerability of the drug. See Also: FDA grants orphan drug status to HI-Bio’s felzartamab for AMR Trend report: how the market for prefilled syringes is evolving in 2024 (and beyond) Another potential AMR therapy approach that was discussed at the meeting was patient-derived neutralising antibody therapy. One such therapy is being developed by the University of Cologne, wherein neutralising antibodies derived from patients with cystic fibrosis could be used against multi-drug resistant Pseudomonas aeruginosa , a common hospital infection. Patients with cystic fibrosis are most at risk of acquiring Pseudomonas infections. “We are currently looking for commercial partnerships to advance the therapy to Phase I trials,” said Alexander Simonis, one of the therapy developers and presenters. Antibody therapies have been very successful as a cancer treatment, with multiple pharmaceutical companies investing in expanding their antibody portfolio . Another novel AMR therapy was Glox Therapeutics’ bacteriocins, an engineered protein that targets drug-resistant pathogenic gram-negative bacteria such as Pseudomonas aeruginosa and Klebsiella pneumoniae . In November 2023, the University of Glasgow and University of Oxford-spinout raised £4.3m ($5.5m) in seed funding to develop bacteriocins against gram-negative bacteria.

Phase 1Orphan DrugImmunotherapy

100 Deals associated with Zosurabalpin

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acinetobacter Infections	Phase 1	China	Roche China Holding Ltd.	15 Feb 2023
Acinetobacter Infections	Phase 1	China	F. Hoffmann-La Roche Ltd.	15 Feb 2023
Bacterial Infections	Phase 1	United States	F. Hoffmann-La Roche Ltd.	03 Dec 2022
Bacterial Infections	Phase 1	France	F. Hoffmann-La Roche Ltd.	03 Dec 2022
Bacterial Infections	Phase 1	Israel	F. Hoffmann-La Roche Ltd.	03 Dec 2022
Bacterial Infections	Phase 1	South Korea	F. Hoffmann-La Roche Ltd.	03 Dec 2022
Bacterial Infections	Phase 1	Moldova	F. Hoffmann-La Roche Ltd.	03 Dec 2022
Acinetobacter Baumannii Infection	Phase 1	United States	Roche Holding AG	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

Zosurabalpin

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation